P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 5, 2013, Pages 525-531

  Zoheir, Naguib ^a   Elhamid, Samah Abd ^a   Abulata, Nelly ^a   Sobky, Mehry El ^b   Khafagy, Doaa ^a   Mostafa, Amr ^c  

^a Faculty of Medicine   (Egypt)

^b RESEARCH INSTITUTE OF OPHTHALMOLOGY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Acute coronary syndrome; clopidogrel; platelet aggregation; platelet polymorphism

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY STENT; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION;

EID: 84879967780     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835e98bf     Document Type: Article

References (19)

1. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3:175-180.
2. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y (AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19:2007-2011.
3. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008; 28:33-38.
4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention).JAm Coll Cardiol 2006; 47:1-121.
5. Bouman HJ, van Werkum JW, Rudez G, Hackeng CM, Leebeek FW, ten Cate H, et al. The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. Thromb Haemost 2012; 107:189-191.
6. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108:989-995.
7. Lee SJ, Jung IS, Jung EJ, Choi JY, Yeo CW, Cho DY, et al. Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Thromb Res 2011; 127:220-227.
8. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25:252-257.
9. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375.
10. Sirotkina OV, Zabotina AM, Berkovich OA, Bazhenova EA, Vavilova TV, Shvartsman AL. Genetic variants of platelet ADP receptor P2Y12 associated with changed platelet functional activity and development of cardiovasculardiseases. Genetika 2009; 45:247-253.
11. Cavallari U, Trabetti E, Malerba G, Biscuola M, Girelli D, Olivieri O, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genetics 2007; 8:59.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramárez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116:491-497.
13. Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Lambert M, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007; 120:893-899.
14. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y (12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119:355-360.
15. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP Receptor Gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25:252-257.
16. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thromb Res 2006; 118:679-683.
17. Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, et al. Outcome comparison of 600-and 300-mg loading doses of clopidogrel in patients undergoing primary PCI for STEMI. Results from the ARMYDA-6 MI (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 2001; 58:1592-1599.
18. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2011; 124:544-554.
19. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, et al. Rationale and design of the randomized, double-blind trial testing intravenous and Oral administration of elinogrel, a selective and reversible P2Y (12)-receptor inhibitor, versus clopidogrel to evaluate Tolerability and Efficacy in non urgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).Am Heart J2010; 160:65-72.